Nathalie Costedoat-Chalumeau French scientist
Costedoat-Chalumeau, Nathalie
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Costedoat-Chalumeau, Nathalie 1967-...
VIAF ID: 213007871 (Personal)
Permalink: http://viaf.org/viaf/213007871
Preferred Forms
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| Contribution of the cardiac MRI during the catastrophic syndrome of the antiphospholipides : about 11 cases. |
|
| Détermination de sous-classes phénotypiques de lupus systématique par une analyse en cluster basée sur les manifestations cliniques : une étude multicentrique de 440 patients |
|
| Etude du rapport bénéfice/ risque du traitement par hydroxychloroquine dans le lupus systématique : étude de la toxicité foetale, de la toxicité cardiaque et optimisation posologique basée sur la détermination de sa concentration sanguine |
|
| A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). |
|
| Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide |
|
| Impact of antiphospholipid biology in maternal Down syndrome screening. |
|
| The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus |
|
| Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases |
|
| Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials." by Gleicher N, Elkayam U, A |
|
| Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients |
|
| Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study |
|
| Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up |
|
| Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. |
|
| « Lupus néonatal » : revue de la littérature |
|
| Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report |
|
| Manifestations rhumatologiques chroniques liées à une primo-infection à parvovirus B19 chez l'adulte : à propos de 2 cas et revue de la littérature |
|
| Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus |
|
| Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil |
|
| Une nouvelle classification des myopathies inflammatoires fondée sur des manifestations cliniques et la présence d'auto-anticorps spécifiques par analyses multidimensionnelles |
|
| Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? |
|
| OP0236 Benefit and safety of antithrombotic treatment in 264 pregnancies in patients with antiphospholipid syndrome |
|
| Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series |
|
| Pathologies maternelles et grossesse |
|
| Pediatric-onset relapsing polychondritis: case series and systematic review |
|
| Pleading to maintain hydroxychloroquine throughout Lupus pregnancies |
|
| Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature |
|
| POTENTIALISATION DES ANTICOAGULANTS ORAUX PAR L'INJECTION INTRAVEINEUSE DE FORTES DOSES DE GLUCOCORTICOIDES |
|
| Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. |
|
| Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. |
|
| Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients |
|
| A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires |
|
| Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block |
|
| Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study |
|
| Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients |
|
| The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis |
|
| Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases |
|
| Renal microaneurysms in three cases of hepatitis C virus-related vasculitis |
|
| Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation |
|
| Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies. |
|
| Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance |
|
| The risk of systemic lupus erythematosus associated with vaccines: an international case-control study |
|
| Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab |
|
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group |
|
| La sarcomania a ses limites! |
|
| SAT0543 Igg4-Related Disease: Clinical and Biological Characteristics in 90 Patients from a Large Multicentric National Registry |
|
| Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease |
|
| Should we treat congenital heart block with fluorinated corticosteroids? |
|
| Small vessel involvement in Takayasu's arteritis |
|
| Spontaneous remission of fully symptomatic visceral leishmaniasis |
|
| State of the art: Reproduction and pregnancy in rheumatic diseases |
|
| Strawberry tongue and red eyes |
|
| Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study |
|
| Systemic lupus erythematosus and antiphospholipid syndrome: How to manage pregnancy? |
|
| Systemic lupus erythematosus: state of the art on clinical practice guidelines |
|
| Systemic sclerosis and prevalence of monoclonal immunoglobulin |
|
| Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres |
|
| Thrombotic microangiopathy and Purtscher-like retinopathy as a rare presentation of juvenile dermatomyositis |
|
| Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome |
|
| Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients |
|
| Training test infectieux |
|
| Treatment adherence in systemic lupus erythematosus and rheumatoid arthritis: time to focus on this important issue: Treatment adherence in SLE and RA. |
|
| Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients |
|
| Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study. |
|
| Ustekinumab: a promising new drug for SLE? |
|
| Vitamin D and autoimmunity. First part: Fundamental aspects |
|
| Vitamine D et Lupus Erythémateux Systémique : Statut vitaminique D dans une cohorte française multicentrique, et relation entre la concentration sérique de 25-hydroxyvitamine D et l' activité de la maladie |
|
| Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? |
|
